Enterprise Capital Management

Enterprise Therapeutics is a clinical-stage biotechnology company focused on developing muco-regulatory therapies for patients with chronic respiratory diseases. The company's research centers on restoring lung function by enhancing mucus clearance, a critical unmet need in conditions like cystic fibrosis and COPD. Their lead asset, ETD001, is a potent, long-acting inhibitor of the epithelial sodium channel (ENaC) designed to increase airway hydration. In 2020, the company successfully sold its TMEM16A potentiator program to Roche, highlighting the strength of its drug discovery platform and its expertise in ion channel pharmacology.